Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimer’s Disease in the Health Care Systems of Different Countries

Author： Jaime Caro   Maribel Salas  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.21, Iss.10, 2004-01, pp. : 677-686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Assessment of Health Economics in Alzheimer's Disease (AHEAD): Treatment with Galantamine in Sweden

By Garfield F.B.  

PharmacoEconomics, Vol. 20, Iss. 9, 2002-09 ,pp. : 629-637

Adis International

Access to resources Recommend Favorite

Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease

By Small G.  

CNS Drugs, Vol. 17, Iss. 12, 2003-01 ,pp. : 905-914

Adis International

Access to resources Recommend Favorite

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

By Wilcock G.  

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 777-789

Adis International

Access to resources Recommend Favorite

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

By Tariot Pierre  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 12, 2001-12 ,pp. : 2027-2049

Informa Healthcare

Access to resources Recommend Favorite

Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease

By Marco-Contelles José   Rodríguez Carolina   García Antonio G  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 5, 2005-05 ,pp. : 575-587

Informa Healthcare

Access to resources Recommend Favorite